Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3009120 in advanced or metastatic cancer
NCT02014116Phase 1Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2013
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of ly3009120 in cancer, metastatic cancer, melanoma and 2 more (9 cohorts), sponsored by Eli Lilly and Company. Primary endpoint: Maximum Tolerated Dose of LY3009120. Started Nov 2013; status: terminated.
02
Drugs
ly3009120
03
Conditions
cancermetastatic cancermelanomanon-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02014116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02014116.